Hematological Malignancies

90 Y Ibritumomab Tiuxetan treatment is completed in 7 days

Rituximab Followed by 90 Y Ibritumomab Tiuxetan THERAPEUTIC DOSE

DOSIMETRIC DOSE

Rituximab

Followed by 111 In Ibritumomab Tiuxetan

Days

0

+1

+2

+3

+4

+5

+6

+7

5 scans

Dosimetric dose: Rituximab 250 mg/m 2 ; 111 In Ibritumomab Tiuxetan 5mCi 111 In, 1.6 mg Ibritumomab Tiuxetan Therapeutic dose: Rituximab 250 mg/m 2 ; 90 Y Ibritumomab Tiuxetan 0.4mCi 90 Y for patients with platelet count >150,000 cells/mm 3 or 0.4 mCi/kg for a platelet count 100,000–149,000 cells/mm 3

Wiseman GA, et al . Eur J Nucl Med 2000; 27: 766–77